Skip to main content

Grafa News and Videos — Page 1265

Latest

Grafa

FDA accepts BioXcel’s at-home agitation drug application for review

BioXcel Therapeutics (NASDAQ:BTAI) announced that the U.S. Food and Drug Administration has formally accepted a supplemental New Drug Application for its lead neuropsychiatric drug, providing a clear regulatory catalyst as the company manages tightening capital constraints.

Read more: FDA accepts BioXcel’s at-home agitation drug application for review
Grafa

PowerBank margins expand to 35% as New York and Ontario solar projects advance

PowerBank (NASDAQ:SUUN) reported a significant expansion in its underlying profit margins and a strengthened balance sheet for the first nine months of fiscal year 2026, driven by systematic execution of its North American clean energy project pipeline.

Read more: PowerBank margins expand to 35% as New York and Ontario solar projects advance
Grafa

Indaptus Therapeutics reassesses decoy platform amid management shakeup and cash crunch

Indaptus Therapeutics (NASDAQ:INDP) announced a sweeping re-evaluation of its core developmental pipeline and resource allocation alongside a significant leadership transition, signaling a strategic pivot as the company faces tightening liquidity constraints.

Read more: Indaptus Therapeutics reassesses decoy platform amid management shakeup and cash crunch

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift